CarbonAI® is Ainnocence's advanced AI platform for small molecule drug discovery, leveraging deep learning models trained on proprietary chemical data to generate novel compounds optimized for target engagement, selectivity, and drug-like properties.2
It forms part of Ainnocence's proprietary sequence-based AI system, enabling ultra-high-throughput virtual screening of up to 10¹⁰ candidates in hours to days without relying on external 3D structure-prediction tools.1
The platform supports de novo design and optimization, with capabilities like SynMagic™ for synthesis planning, and has contributed to 60+ successful deliveries with 10%-60% wet lab hit rates across therapeutic programs including small molecules.123
Ainnocence's AI therapeutic discovery platform, including CarbonAI, reduces wet lab iterations by over 80%, expands undruggable target space by 75%, and has been applied in 60+ programs covering small molecules, antibodies, and cell therapies.13